Literature DB >> 20033348

SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis.

Cíntia dos Santos Costa1, Thais Ortiz Hammes, Francieli Rohden, Rogério Margis, Josiane Woutheres Bortolotto, Alexandre Vontobel Padoin, Cláudio Cora Mottin, Regina Maria Guaragna.   

Abstract

BACKGROUND: Visceral adipose tissue is known to release greater amounts of adipokines and free fatty acids into the portal vein, being one of the most predictive factors of nonalcoholic fatty liver disease (NAFLD). Our study has the purpose to evaluate sirtuin 1 (SIRT1), adiponectin, Forkhead/winged helix (FOXO1), peroxisome proliferator-activated receptor (PPAR)gamma1-3, and PPARbeta/delta mRNA expression in morbidly obese patients in three different lipid depots: visceral (VAT), subcutaneous (SAT), and retroperitoneal (RAT). Recent studies suggest that SIRT1, a NAD(+)-dependent deacetylase, protects rats from NAFLD.
METHODS: We divided the patients in two groups: those with slight or moderate steatosis (hepatic steatosis, HS) and other comprising individuals with severe steatosis associated or not with necroinflammation and fibrosis (severe hepatic steatosis, SHS). The adipose tissue depots were obtained during bariatric surgery. Total RNAs were extracted using TRIzol. The amount of genes of interest was determined by quantitative real-time polymerase chain reaction.
RESULTS: When comparing the two groups of patients, a decrease in SIRT1 was observed in VAT of morbidly obese patients in SHS group (p = 0.006). The mRNA expression of the other genes showed no differences in VAT. No difference was found either in SAT or in RAT for all genes in the study. In addition, the homeostasis model assessment for insulin resistance (HOMA-IR) value was higher in SHS group compared to HS (p = 0.006). Also, our results show that the mRNA expression of SIRT1 and the value of HOMA-IR were positively correlated in VAT of SHS patients (r = 0.654; p = 0.048).
CONCLUSIONS: Downregulation of SIRT1 mRNA expression in VAT of SHS could be possible impairing mitochondria biogenesis and fatty acid oxidation, promoting severe steatosis in obese patients. Our results provide a possible proof of SIRT1 protective potential in VAT against NAFLD in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033348     DOI: 10.1007/s11695-009-0052-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  47 in total

Review 1.  Obesity and the regulation of energy balance.

Authors:  B M Spiegelman; J S Flier
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Regional differences in protein production by human adipose tissue.

Authors:  P Arner
Journal:  Biochem Soc Trans       Date:  2001-05       Impact factor: 5.407

3.  Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease.

Authors:  Cem Aygun; Omer Senturk; Saadettin Hulagu; Suleyman Uraz; Altay Celebi; Tolga Konduk; Birsen Mutlu; Zeynep Canturk
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 2.566

4.  Molecular links between aging and adipose tissue.

Authors:  F Picard; L Guarente
Journal:  Int J Obes (Lond)       Date:  2005-03       Impact factor: 5.095

5.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

Authors:  Yong-Xu Wang; Chih-Hao Lee; Sambath Tiep; Ruth T Yu; Jungyeob Ham; Heonjoong Kang; Ronald M Evans
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

6.  Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance.

Authors:  Ancha Baranova; Shobha J Gowder; Karen Schlauch; Hazem Elariny; Rochelle Collantes; Arian Afendy; Janus P Ong; Zachary Goodman; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2006-09       Impact factor: 4.129

7.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.

Authors:  Joseph T Rodgers; Carlos Lerin; Wilhelm Haas; Steven P Gygi; Bruce M Spiegelman; Pere Puigserver
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

Review 8.  A therapeutic role for sirtuins in diseases of aging?

Authors:  C H Westphal; M A Dipp; L Guarente
Journal:  Trends Biochem Sci       Date:  2007-11-05       Impact factor: 13.807

9.  Adipose tissue distribution and quantification of PPARbeta/delta and PPARgamma1-3 mRNAs: discordant gene expression in subcutaneous, retroperitoneal and visceral adipose tissue of morbidly obese patients.

Authors:  Josiane Woutheres Bortolotto; Rogério Margis; Angela Cristine Bersch Ferreira; Alexandre Vontobel Padoin; Cláudio Cora Mottin; Regina Maria Guaragna
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

Review 10.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

View more
  37 in total

1.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

2.  Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1-3 mRNA expression in human visceral adipocytes.

Authors:  Cíntia dos Santos Costa; Francieli Rohden; Thais Ortiz Hammes; Rogério Margis; Josiane Woutheres Bortolotto; Alexandre Vontobel Padoin; Cláudio Cora Mottin; Regina Maria Guaragna
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

3.  Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.

Authors:  Supriya R Kulkarni; Carol J Soroka; Lee R Hagey; James L Boyer
Journal:  Hepatology       Date:  2016-10-28       Impact factor: 17.425

4.  Targeting sirtuins for the treatment of diabetes.

Authors:  Frank K Huynh; Kathleen A Hershberger; Matthew D Hirschey
Journal:  Diabetes Manag (Lond)       Date:  2013-05-01

Review 5.  Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?

Authors:  Carles Cantó; Johan Auwerx
Journal:  Pharmacol Rev       Date:  2011-11-21       Impact factor: 25.468

6.  Sirtuins 1-7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia.

Authors:  Stefania Mariani; Giuliana Di Rocco; Gabriele Toietta; Matteo A Russo; Elisa Petrangeli; Luisa Salvatori
Journal:  Endocrine       Date:  2016-11-14       Impact factor: 3.633

Review 7.  SIRT1 and other sirtuins in metabolism.

Authors:  Hung-Chun Chang; Leonard Guarente
Journal:  Trends Endocrinol Metab       Date:  2013-12-30       Impact factor: 12.015

Review 8.  Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease.

Authors:  Sara Heebøll; Karen Louise Thomsen; Steen B Pedersen; Hendrik Vilstrup; Jacob George; Henning Grønbæk
Journal:  World J Hepatol       Date:  2014-04-27

9.  Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars.

Authors:  Xiao-Zhi Bai; Jia-Qi Liu; Long-Long Yang; Lei Fan; Ting He; Lin-Lin Su; Ji-Hong Shi; Chao-Wu Tang; Zhao Zheng; Da-Hai Hu
Journal:  Br J Pharmacol       Date:  2016-03-23       Impact factor: 8.739

10.  Nutrient sensor-mediated programmed nonalcoholic fatty liver disease in low birthweight offspring.

Authors:  Diana Wolfe; Ming Gong; Guang Han; Thomas R Magee; Michael G Ross; Mina Desai
Journal:  Am J Obstet Gynecol       Date:  2012-07-31       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.